HCT
FDA Approves Livtencity for Post-Transplant Recipients With Refractory CMV
The FDA approved maribavir (Livtencity, Takeda) as the first drug for treating patients 12 years of age and older ...
NOVEMBER 24, 2021
Speedier Busulfan Washout A Plus in HCT Conditioning?
The washout period between the last dose of metronidazole and the first dose of the alkylating agent busulfan can ...
JULY 13, 2021
Fostering Global Antimicrobial Stewardship for HCT Patients
A multidisciplinary team at The Ohio State University has implemented a pharmacist mentoring program to assist ...
NOVEMBER 13, 2018
Trial Is Assessing KRd Versus KCd in Newly Diagnosed MM Pts
Chicago—As an induction therapy in newly diagnosed, relatively young patients with multiple myeloma (MM), ...
JUNE 30, 2017
Inpatient Palliative Intervention Benefits Patients Undergoing HCT
San Francisco—Inpatient palliative care improves quality of life (QOL), symptom burden, depression and ...
OCTOBER 6, 2016
BMT Tandem Meetings: Expert Q&A on Key Abstracts
Hematopoietic cell transplantation (HCT) is playing an increasing role in the management of many hematologic ...
JUNE 9, 2016
Evidence Accrues for Haploidentical Transplants
A haploidentical related donor may be a better choice than a matched unrelated donor (MUD) for hematopoietic cell ...
MAY 9, 2016
HCT Offers AML Patients Sizable Long-Term Survival Benefit
Orlando, Fla.—A registry has documented relatively high rates of long-term survival among patients with ...
APRIL 21, 2016
